Abstract 563P
Background
Osimertinib, the standard first-line therapy for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC), preliminarily demonstrated similar clinical effectiveness to the landmark FLAURA study in the prospective, non-interventional, real-world FLOURISH study at the first interim analysis. This report presents an updated effectiveness and safety results.
Methods
A total of 500 patients were recruited into the FLOURISH study from 22 sites in China between July 27, 2020, and April 27, 2022. This analysis included 460 patients who met the eligibility criteria and received at least one dose of osimertinib after enrolment and without protocol violation into the full analysis set (FAS) for effectiveness analysis, and 495 patients who received at least one dose of osimertinib after enrolment into the safety set (SS). The data cut-off date was June 30, 2023.
Results
Of the 460 patients in FAS, the median age was 64.1 years (range: 27-88), 62.4% were female, 64.8% had comorbidities, 35.0% with CNS metastases, and 98.7% in stage IIIB-IV. The objective response rate (ORR) was 61.8% (238/385), and disease control rate (DCR) was 96.1% (370/385) in evaluable patients. With a median follow-up of 18.0 months, the 1-year progression-free survival (PFS) and 1-year overall survival (OS) rate was 79.6% (95%CI: 75.0%-83.3%) and 90.0% (95%CI: 86.8%-92.5%), respectively. In patients with CNS metastases, ORR was 63.8% (90/141), DCR was 95.0% (134/141), 1-year PFS rate was 78.9%, and 1-year OS rate was 90.1%. Moreover, patients with exon 19 deletion (n=235) had higher 1-year PFS (84.2% vs. 75.0%) and 1-year OS (93.4% vs. 86.8%) rates than patients with exon 21 L858R (n=212). Among the 495 patients in SS, 195 patients (39.4%) experienced adverse events (AEs), with 18(3.6%) of grade ≥3. AEs leading to dose interruption or discontinuation were reported in 3 (0.6%) and 12(2.4%) patients, respectively.
Conclusions
The FLOURISH study showed consistence with FLAURA in terms of effectiveness of first-line osimertinib for Chinese patients with advanced EGFRm-NSCLC in real world setting. No new safety signals were observed. The follow-up is still ongoing and the final analysis is expected in future.
Clinical trial identification
NCT04391283.
Editorial acknowledgement
Legal entity responsible for the study
Guangdong Association of Clinical Trials.
Funding
AstraZeneca China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract